Trinity Biotech plc announced on July 1, 2025, that it believes it reached a critical profitability inflection point during the latter part of Q2 2025. The company projects it achieved Adjusted EBITDA-positive operations during Q2 2025 and expects to remain Adjusted EBITDA-positive going forward. This reflects continued strong execution on its comprehensive transformation plan.
The company now expects to be meaningfully Adjusted EBITDA-positive and cash flow positive from its ongoing operating activities starting Q3 2025 and into the foreseeable future. This milestone is a key indicator of the success of its strategic turnaround efforts. The company also released details regarding its results for the quarter ended March 31, 2025, with a full presentation available on its website.
This projected shift to profitability and positive cash flow from operations is a significant development for Trinity Biotech. It underscores the impact of its operational efficiencies and strategic initiatives aimed at creating a stronger financial foundation and delivering long-term value.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.